No Data
No Data
Earnings Preview: CSTL to Report Financial Results Post-market on November 04
Castle Biosciences Presents Award-Winning Abstract at ACG 2024 Demonstrating Ability of Its TissueCypher Test to Significantly Reduce Healthcare Costs Associated With the Management of Barrett's Esophagus Patients
The Analyst Landscape: 4 Takes On Castle Biosciences
Castle Biosciences Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Castle Biosciences(CSTL.US) With Buy Rating, Raises Target Price to $42
Express News | Castle Biosciences Inc : Canaccord Genuity Raises Target Price to $42 From $35